Exclusive Summary

• First-in-Class Dominance: Being the world's first approved AKT inhibitor, it masterfully tackles the immense, rigid clinical unmet needs associated with prior endocrine/CDK4/6 resistance in advanced HR+/HER2- breast cancers.
• Hyper-Accelerated Time-to-Market: Aiming for an aggressive 2027 US FDA ANDA submission, the generic strictly sits in the global top-tier, empowering distribution partners to capture exclusive 'First-to-Launch' or 'Day-1' windfalls in emerging territories.
• Uncompromised Quality & Compliance: Developed meticulously alongside utmost US FDA cGMP strictures and precise CTD protocols, eliminating typical registration hurdles across diversified global regulatory frameworks.
• Disruptive Cost Reductions: Bypassing the astonishing >$20,000/month originator burden, it handsover formidable cost flexibilities to overseas distributors to effortlessly conquer local reimbursements and private out-of-pocket sectors.